Literature DB >> 26641633

IgG4-Associated Cholangitis--A Mimic of PSC.

Ulrich Beuers, Lowiek M Hubers, Marieke Doorenspleet, Lucas Maillette de Buy Wenniger, Paul L Klarenbeek, Kirsten Boonstra, Cyriel Ponsioen, Erik Rauws, Niek de Vries.   

Abstract

IgG4-associated cholangitis (IAC) is an inflammatory disorder of the biliary tract representing a major manifestation of IgG4-related disease (IgG4-RD) often with elevation of serum IgG4 levels, infiltration of IgG4+ plasma cells in the affected tissue and good response to immunosuppressive treatment. Its first description may go back to 150 years ago. The clinical presentation of IAC is often misleading, mimicking other biliary diseases such as primary sclerosing cholangitis (PSC) or cholangiocarcinoma. The HISORt criteria--histopathological, imaging, and serological features (sIgG4), other organ manifestations of IgG4-RD and response to treatment--are the standard for the diagnosis of IAC. In this overview of a recent lecture, we summarize our original findings on IgG4-RD that (i) dominant IgG4+ B-cell clones identified by advanced next generation sequencing (NGS) are highly specific for IgG4-RD (meanwhile confirmed by others), are a highly accurate diagnostic marker to distinguish IgG4-RD from PSC and biliary/pancreatic malignancies and may be crucial in unravelling the pathophysiology of IgG4-RD; (ii) sIgG4/sIgG1 >0.24 have additional diagnostic value in comparison to sIgG4 in differentiating IAC from PSC; (iii) blood IgG4 mRNA is a highly accurate diagnostic marker comparable to NGS and may become an easily available and affordable diagnostic standard for distinguishing IgG4-RD from PSC and biliary/pancreatic malignancies; and (iv) 'blue collar work' with long-term exposure to solvents, paints, oil products or industrial gases may be a risk factor for development of IgG4-RD. These findings may contribute to the understanding of the pathophysiology and to the early diagnosis and adequate treatment of IgG4-RD.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26641633     DOI: 10.1159/000440830

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  5 in total

1.  Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis.

Authors:  Sung-Hoon Moon; Myung-Hwan Kim; Jong Kyun Lee; Seunghee Baek; Young Sik Woo; Dong Hui Cho; Dongwook Oh; Tae Jun Song; Do Hyun Park; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  J Gastroenterol       Date:  2016-07-28       Impact factor: 7.527

2.  Clinical Utility of Personalized Serum IgG Subclass Ratios for the Differentiation of IgG4-Related Sclerosing Cholangitis (IgG4-SC) from Primary Sclerosing Cholangitis (PSC) and Cholangiocarcinoma (CCA).

Authors:  Jae Keun Park; Dongwuk Kim; Jeong Min Lee; Kwang Hyuck Lee; Kyu Taek Lee; Joo Kyung Park; Jong Kyun Lee
Journal:  J Pers Med       Date:  2022-05-24

Review 3.  [IgG4-associated cholangitis - clinical presentation of an overlooked disease entity].

Authors:  T Herta; J Verheij; U Beuers
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

Review 4.  The changing faces of cholangitis.

Authors:  Sum P Lee; Joseph R Roberts; Rahul Kuver
Journal:  F1000Res       Date:  2016-06-17

Review 5.  IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis.

Authors:  Atsushi Tanaka
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.